Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 µg/day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I)
|
|
- Olivia Fox
- 5 years ago
- Views:
Transcription
1 EXPERIMENTAL SCIENCE Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 µg/day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I) Michael A. Singer, MD; Dan M. Miller, MD, PhD; Jeffrey G. Gross, MD; Craig M. Greven, MD; Barry Kapik, MS; Clare Bailey, MD, FRCOphth; Faruque Ghanchi, MBBS, FRCOphth; Baruch D. Kuppermann, MD, PhD INTRODUCTION BACKGROUND AND OBJECTIVE: Visual outcomes of the FAME study (0.2 µg/day fluocinolone acetonide [FAc]) and Protocol I (0.5 mg ranibizumab plus deferred laser) were compared using the area under the curve (AUC) analysis method. PATIENTS AND METHODS: Best-corrected visual acuity (BCVA) data collected during a period of 3 years of follow-up for patients enrolled in FAME or Protocol I were used to calculate AUC of the change in BCVA over a time curve. RESULTS: In the overall population, there was a greater treatment effect for ranibizumab plus deferred laser compared with FAc. However, for subgroups of pseudophakic eyes, eyes with chronic diabetic macular edema (DME), and pseudophakic eyes with chronic DME, ranibizumab plus deferred laser and FAc were not found to be significantly different. The ranibizumab group received a median of 14 injections during a 36-month period compared with a mean of 1.3 injections in the FAc group. CONCLUSION: In pseudophakic and chronic DME subgroups, FAc was comparable to ranibizumab plus deferred laser with fewer injections. [Ophthalmic Surg Lasers Imaging Retina. 2018;49: ] Diabetic macular edema (DME) is a severe, visionthreatening stage of diabetic retinopathy (DR) a leading cause of vision loss worldwide. 1 Although intravitreal anti-vascular endothelial growth factor (VEGF)-A injections have been demonstrated as effec- From University of Texas Health Science Center, San Antonio (MAS); Cincinnati Eye Institute, Cincinnati (DMM); Carolina Retina Center, Columbia, SC (JGG); Wake Forest Baptist Medical Center, Winston Salem, NC (CMG); Alimera Sciences, Alpharetta, GA (BK); University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom (CB); Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom (FG); and UC Irvine Health Gavin Herbert Eye Institute, Irvine, CA (BDK) Singer, Miller, Gross, etc.; licensee SLACK Incorporated. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International ( licenses/by/4.0). This license allows users to copy and distribute, to remix, transform, and build upon the article, for any purpose, even commercially, provided the author is attributed and is not represented as endorsing the use made of the work. Originally submitted January 17, Revision received June 21, Accepted for publication August 3, This study was presented at the American Academy of Ophthalmology Annual Meeting, New Orleans, November 11-14, Financial support for this study was provided by Alimera Sciences (Alpharetta, GA). The sponsor participated in data collection, data management, data analysis, interpretation of the data, preparation of the manuscript, and review of the manuscript. Employees of Alimera Sciences participated in conducting the study, data acquisition analysis, and reporting. Dr. Singer has received financial support from Aerpio, Allergan, Ampio, Genentech, and Regeneron. Dr. Miller has received financial support from Alcon, Genentech, and Regeneron; has been a consultant for Alimera and Bausch + Lomb; and has a personal financial interest in Vortex. Dr. Gross has received financial support from Acucela, Ohr, and Regeneron. Dr. Greven is involved in clinical trials with Genentech (Roche) and Allergan. Mr. Kapik is an employee of Alimera Sciences. Dr. Bailey is a consultant for Allergan, Alcon, Bayer, Alimera Sciences, Roche and Novartis. Dr. Ghanchi has been a consultant for Alimera, Allergan, Bayer, and Novartis and has received grants and funding from Allergan, Bayer, Novartis, psivida, Oraya, and Sakura. Dr. Kuppermann is involved in clinical research with Alcon, Alimera, Allegro, Allergan, Apellis, Genentech, GSK, J-Cyte, Neurotech, Ophthotech, Regeneron, and ThromboGenics, and has been a consultant for Aerpio, Alcon, Alimera, Allegro, Allergan, Ampio, Dose, Genentech, Glaukos, Novartis, Ophthotech, Regeneron, and SciFluor. The authors thank Shuo Yang, PhD, of Quorum Consulting for statistical support. Medical writing assistance was provided by Emma Mycroft at Helios Medical Communications, supported by Alimera Sciences. Address correspondence to Michael A. Singer, MD, 9157 Huebner Rd., San Antonio, TX 78240; msinger11@me.com. doi: / Ophthalmic Surgery, Lasers & Imaging Retina Healio.com/OSLIRetina
2 Figure 1. Integrated FAME trials study design, forming the FAME study. 14 BCVA = best-corrected visual acuity; DME = diabetic macular edema; FAc = fluocinolone acetonide tive in managing DME, reducing progression of DR, and treating neovascularization, 2,3 a broad spectrum of inflammatory events drives the pathogenesis and progression of DR 4 and the multifactorial nature of DR at all levels of severity has been established in human eyes. 5 The importance of continuous therapy to maintain the disease-modifying effects of pharmacotherapy on DR has been demonstrated in two separate reports, in which a reduction in injection frequency of anti-vegf therapy following a monthly injection regimen has resulted in worsening of DR. 6,7 The fluocinolone acetonide (FAc) 0.2 µg/day implant (Iluvien; Alimera Sciences, Alpharetta, GA) delivers the only continuous, multiyear therapy for DME as a daily micro-dose of FAc (0.2 µg/day) for 36 months. 8 Sustained, low-dose intravitreal steroid released by FAc 0.2 μg/day implants has been shown to reduce neuroinflammation in animal models. 9 In the FAME study, which compared efficacy in terms of change in best-corrected visual acuity (BCVA) for FAc 0.2 µg/day implant versus sham control in patients with DME, 8 the FAc implant demonstrated significant vision improvement in patients with DME for up to 36 months 8 and has also shown significant effects on slowing progression of proliferative DR and improving DR. 10 The area under the curve (AUC) method of efficacy analysis is an alternative measure of change in visual acuity (VA) that captures treatment benefit over an entire dosing/observation period, in contrast with typical measures of efficacy, which are based on a single time point measurement. For multiyear studies this is particularly relevant, especially considering the potential impact of shortterm data fluctuations when outcomes are assessed using individual time points. In addition, realworld treatment regimens often do not match those employed in pivotal clinical trials for short-acting therapies requiring regular intravitreal injections. September 2018 Vol. 49, No
3 Figure 2. DRCR.net Protocol I study design; data from sham and deferred laser treatment arms were incorporated into the current analysis. BCVA = best-corrected visual acuity; DME = diabetic macular edema AUC is being recognized as an important measure of therapy benefit for DR and has been previously used to assess the effect of anti-vegf therapy on proliferative DR. 3 The current analysis used the AUC method to compare the efficacy of FAc 0.2 µg/day with sham control to evaluate the FAc 0.2 µg/day implant in the treatment of DME. In addition, a comparative analysis was conducted with the publicly available Protocol I dataset, 11 where the AUC for the ranibizumab (Lucentis; Genentech, South San Francisco, CA) plus deferred laser arm was calculated. This arm was chosen because it had the best outcomes and is generally recognized as more closely reflecting the current standard of care. The AUC method is intended to allow more robust statistical comparison between trials than conventional measures of efficacy; additionally, these studies have similar inclusion and exclusion criteria. However, differences between the studies, such as the lack of a chronic subpopulation in Protocol I, introduce limitations to the current analysis. PATIENTS AND METHODS The FAME study, 12 consisting of two randomized, double-masked, sham injection-controlled, parallelgroup, multicenter trials (FAME A and B), was conducted during a 36-month period, as previously described. 13 Patients were randomized in a 2:1 ratio to FAc 0.2 µg/day or sham control injection. Treatment was administered to the study eye only (Figure 1). 14 At each visit, BCVA was assessed using either Early Treatment Diabetic Retinopathy Study (ETDRS) charts at 4 m or an electronic ETDRS (E-ETDRS) test at 3 m. The DRCR.net Protocol I trial 15 was a randomized, multicenter study conducted during a 36-month period (Figure 2). 2,16 Patients were randomly assigned to groups: sham injection plus prompt laser, ranibizumab 0.5 mg plus prompt laser, ranibizumab 0.5 mg plus deferred laser, or triamcinolone 4 mg plus prompt laser. Prompt laser was applied 3 to 10 days after the initial ranibizumab injection; deferred laser was applied at least 24 weeks following ranibizumab injection. In subjects with two eligible eyes, the right eye was randomly assigned to a treatment group; the left eye was assigned to sham plus prompt laser. AUC was calculated from the observed change in BCVA letter score from baseline through Month 36 using the trapezoidal rule. 3 For each subject, the summarized variable represented total AUC divided by the total number of days in the study. Individual patient AUC data were then used to calculate mean AUC for each subgroup. AUC analysis was performed for individual FAc 0.2 µg/day trials (FAME A and B) and the combined study 700 Ophthalmic Surgery, Lasers & Imaging Retina Healio.com/OSLIRetina
4 Figure 3. Summary of BCVA letter score and illustrative comparison of AUC analysis from (A) FAME A and (B) FAME B trials. AUC = area under the curve; BCVA = bestcorrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; FAc = fluocinolone acetonide population and compared with AUC for ranibizumab plus deferred laser in DRCR.net Protocol I. This arm was selected because it was considered to have an optimal BCVA outcome compared with the ranibizumab plus prompt laser and triamcinolone plus prompt laser arms. From baseline to Year 1, 75.5% of eyes in the ranibizumab plus deferred laser group, 69.0% of eyes in the ranibizumab plus prompt laser group, and 50.0% of eyes in the triamcinolone plus prompt laser group experienced a five-letter or greater improvement. From baseline to Year 5, 73.9% of eyes in the ranibizumab plus deferred laser arm experienced a five-letter or greater improvement compared with 66.1% of eyes in the ranibizumab plus prompt laser arm. 2,16 Further analyses were conducted on pseudophakic eyes (FAME and Protocol I), chronic DME eyes (DME duration 3 years, FAME only), and pseudophakic plus chronic DME eyes (FAME only). RESULTS Study Population In total, 953 patients were assessed in the FAME study with a mean age of 62.5 years; 188 participants were included in the ranibizumab plus deferred laser arm of Protocol I, with a mean age of 64 years. Baseline characteristics are further described in Table 1. 2,13 September 2018 Vol. 49, No
5 Figure 4. Summary of BCVA letter score and illustrative comparison of AUC from mean BCVA scores for FAc 0.2 µg/day and ranibizumab plus deferred laser: all cases, 3-year follow-up. AUC = area under the curve; BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; FAc = fluocinolone acetonide Number of FAc Treatments The number of FAc treatments administered during the FAME study was consistent across lens status and DME duration subgroups (Table 2). FAME AUC Outcomes A significant AUC-based treatment effect was observed for the FAc 0.2 µg/day implant versus sham control for FAME A and B independently (P =.03 and P <.001, respectively) (Figure 3). FAME Versus Protocol I Ranibizumab Plus Deferred Laser There was a significantly greater treatment effect for ranibizumab plus deferred laser compared with 0.2 µg/day FAc during the course of 36 months (8.43 letters/day compared with 5.18 letters/day, respectively; P =.002) (Figure 4). For pseudophakic and chronic DME subgroups, the AUC with FAc 0.2 µg/day compared with ranibizumab plus deferred laser was not found to be significantly different (P =.77 and P =.19, respectively) (Figure 5). For pseudophakic plus chronic DME eyes treated with FAc 0.2 µg/day and pseudophakic eyes treated with ranibizumab plus deferred laser, AUC was not significantly different (P =.90) (Figure 6). DISCUSSION The comparison of VA outcomes provided by the AUC method is more representative of the treatment effect over time than comparisons based on a single time point. This is especially true in larger studies, in which individual time points for comparison may vary considerably. AUC significantly favored FAc 0.2 µg/day during a period of 36 months compared with sham control in the FAME study. This outcome was replicated in the individual FAME A and B trials. In the overall FAME study population, the 36-month AUC was significantly greater for ranibizumab plus deferred laser than for FAc 0.2 µg/day (P =.002), partly because AUC was depressed in the FAc 0.2 µg/day group as a result of cataract development during the 12- to 18-month time period and consequent loss of VA (Figure 4). In a separate analysis of the FAME data, approximately 50% of patients (n = 188) treated with FAc 0.2 µg/day in the overall FAME study group underwent cataract extraction during the follow-up period. 17 Of the patients who underwent cataract extraction during the follow-up period, 52% (n = 97) had chronic DME. 17 Only 17% of patients in the sham group of the FAME study received cataract extraction during the follow-up period Ophthalmic Surgery, Lasers & Imaging Retina Healio.com/OSLIRetina
6 Figure 5. Summary of BCVA letter score and illustrative comparison of AUC from mean BCVA scores for FAc 0.2 µg/day and ranibizumab plus deferred laser: (A) Pseudophakic cases; (B) Chronic DME (DME duration 3 years) eyes and overall patient population. AUC = area under the curve; BCVA = best-corrected visual acuity; DME = diabetic macular edema; ETDRS = Early Treatment Diabetic Retinopathy Study; FAc = fluocinolone acetonide In this analysis of the FAME results and Protocol I, the visual outcomes achieved in pseudophakic cases treated with FAc 0.2 µg/day were not significantly different to those treated with ranibizumab plus deferred laser (P =.77). There was also no significant difference between the visual outcomes achieved in chronic DME treated with FAc 0.2 µg/ day and those of all Protocol I participants treated with ranibizumab plus deferred laser (P =.19). Cataract development and elevation of intraocular pressure (IOP) are known side-effects of intravitreal corticosteroid treatment; 8 the incidence of these ocular adverse events was greater in FAc treatment compared with ranibizumab treatment. Cataract was the most common adverse event in the FAME study, affecting 42.7% of all patients and 81.7% of phakic patients treated with the FAc 0.2 µg/day implant; IOP elevation considered an adverse event was observed in 37.1% of FAc 0.2 µg/day-treated patients compared with 11.9% of sham-control patients. 8 In the first year of Protocol I follow-up, only 6% of patients treated with ranibizumab plus deferred laser who were phakic at baseline required cataract extraction; seven eyes treated with ranibizumab plus deferred laser (4%) had either IOP elevation 10 mm Hg or greater, IOP increased to 30 mm Hg or greater, or initiation of IOP-lowering medication. 2 September 2018 Vol. 49, No
7 Figure 6. Summary of BCVA letter score and illustrative comparison of AUC from mean BCVA scores for FAc 0.2 µg/day (pseudophakic eyes with chronic diabetic macular edema) and ranibizumab plus deferred laser (pseudophakic cases). AUC = area under the curve; BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; FAc = fluocinolone acetonide The clinical benefit of FAc 0.2 µg/day appears to be comparable to that of ranibizumab plus deferred laser in pseudophakic and chronic DME eyes, as demonstrated by AUC analysis, with a lesser treatment burden. During the 36-month evaluation period, patients who received FAc 0.2 µg/day required a mean of 1.3 treatments irrespective of DME duration or baseline lens status. In contrast, the ranibizumab group required a median of 14 injections. Treatment with the FAc 0.2 µg/day implant therefore provides an alternative to anti-vegf therapy which, in selected patients, could provide similar benefit with a reduced treatment burden. A limitation of this analysis is its post-hoc nature and the fact that it involves clinical data from two different studies. Although conclusive statements cannot be made based on meta-type analyses, these comparisons are still valuable given that there are no head-to-head clinical trials comparing these two agents, which are both approved to treat DME in the US and chronic DME in Europe Even with these limitations, it should also be recognized that the ranibizumab plus deferred laser arm was specifically chosen because this is the ranibizumab arm in Protocol I with the optimal outcome. 3 Rather than combine the data for ranibizumab from the two arms, we felt that using only the arm with the best outcome offset some of the other limitations of this analysis. The ranibizumab plus deferred laser arm was also the most clinically relevant and reflective of the FAME study protocol in terms of additional therapies. Indeed, in the FAME study, rescue laser was only allowed 6 weeks after FAc was administered and subsequent treatments were allowed as frequently as every 12 months for persistent or recurrent edema. 8 In Protocol I, focal/ grid laser treatment was applied either promptly (3 to 10 days after the initial ranibizumab injection) or was deferred for at least 24 weeks. Additionally, with any comparisons between the FAME study and other phase 3 clinical trials for DME pharmacotherapies, it is important to recognize differences in the study population. For example, chronic and chronic-pseudophakic subgroups were not analyzed in Protocol I. Unlike most phase 3 studies, the population enrolled in FAME did not include any treatment-naive DME patients. This means that the FAME study population may have had more severe DME with potentially irreversible damage, which would only reduce the treatment effect seen 704 Ophthalmic Surgery, Lasers & Imaging Retina Healio.com/OSLIRetina
8 TABLE 1 Baseline Characteristics 2,13 FAME Protocol I Sham Control FAc 0.2 µg/day Ranibizumab Plus Deferred Laser Participants, n Age (Mean), Years Male, % Duration of Diabetes (Median, Interquartile Range), Years 16 (11 21) 16 (11 22) 17 (11 22) HbA1c (Median, Interquartile Range), % 7.4 ( ) 7.6 ( ) 7.5 ( ) Lens Status, % Phakic / % Pseudophakic 65 / / / 29* *28% posterior chamber intraocular lens, 1% anterior chamber intraocular lens FAc = fluocinolone acetonide; HbA1c = glycated hemoglobin TABLE 2 Fluocinolone Acetonide Treatments Administered During the FAME Study by Lens Status and Duration of DME Lens Status Pseudophakic 1.3 ± 0.5 Phakic 1.3 ± 0.6 DME Duration Chronic ( 3 years) 1.3 ± 0.6 Non-chronic (< 3 years) 1.3 ± 0.5 FAc = fluocinolone acetonide; SD = standard deviation; DME = diabetic macular edema Number of FAc Treatments (Mean ± SD) in the population. Although there were no approved pharmaceutical therapies for DME when the key phase 3 clinical study (FAME) was initiated, three pharmaceutical therapies have since been approved for the treatment of DME However, no comparison between FAc and these additional pharmaceutical therapies has yet been performed. The results of the Protocol I analysis of ranibizumab and laser treatment are now publicly available. 11 This meta-analysis comparison of the two studies was undertaken after the publication of the Protocol I analysis. The treatment burden, visual outcomes, and adverse events associated with each treatment were compared to allow clinicians to adjudicate the respective benefits of each treatment for their patients. Analyses of the impact of FAc treatment on DME are ongoing. However, there is an improvement in treatment burden with the FAc implant, which will have an impact on patient compliance and quality of life. An economic benefit may also be observed as a result of better DME management and fewer treatments. 25 REFERENCES 1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3): Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6): Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA. 2015;314(20): Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin September 2018 Vol. 49, No
9 Eye Res. 2011;30(5): Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19: Bressler SB, Liu DL, Glassman AR, et al. Change in diabetic retinopathy through 2 years: Secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. JAMA Ophthalmol. 2017;135(6): Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS, RIDE and RISE Research Group. Outcomes with as-needed ranibizumab after initial monthly therapy: Long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology. 2015;122(12): Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10): Glybina IV, Kennedy A, Ashton P, Abrams GW, Iezzi R. Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. Invest Ophthalmol Vis Sci. 2010;51(8): Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017;124(4): Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema (LRT for DME). Clinicaltrials.gov. show/nct Accessed October 3, Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema (FAME). Clinicaltrials. gov. Accessed October 3, Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4): Singer M. Efficacy assessment of the 0.2 mg/day fluocinolone acetonide (FAc) intravitreal implants vs. sham control using the area under the curve (AUC) method. Poster presented at: American Society of Retina Specialists 34th Annual Meeting; August 9-14, 2016; San Francisco, CA. 15. Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy (LRTforDME+PRP). Clinicaltrials.gov. Accessed October 3, Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2): Yang Y, Bailey C, Holz FG, et al. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye (Lond). 2015;29(9): Iluvien 190 micrograms intravitreal implant in applicator; summary of product characteristics EMc website. Accessed October 3, Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection; highlights of prescribing information. 2014a. label/2014/201923s000lbl.pdf. Accessed October 3, Lucentis intravitreal injection; prescribing information. 2014b. label/2014/125156s105lbl.pdf. Accessed October 3, Lucentis 10 mg/ml solution for injection; summary of product characteristics Accessed October 3, United States Food and Drug Administration Supplement Orig1s0069,s0076ltr.pdf. Accessed May 24, United States Food and Drug Administration Supplement Orig1s037ltr.pdf. Accessed May 24, United States Food and Drug Administration Supplement Orig1s009ltr.pdf. Accessed May 24, Quhill F, Beiderbeck A. Cost advantage of fluocinolone acetonide implant (Iluvien) versus ranibizumab in the treatment of chronic diabetic macular oedema. Glob Reg Health Technol Assess. 2017;4:e155-e Ophthalmic Surgery, Lasers & Imaging Retina Healio.com/OSLIRetina
ILUVIEN IN DIABETIC MACULAR ODEMA
1 ILUVIEN IN DIABETIC MACULAR ODEMA Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars conference 2104 1 2 Declaration of interest I have sat on Advisory boards for
More informationTargeting Inflammation in Diabetic Macular Edema: From Basic Science to Clinical Trials to Clinical Practice
Targeting Inflammation in Diabetic Macular Edema: From Basic Science to Clinical Trials to Clinical Practice Baruch D Kuppermann, MD, PhD Professor of Ophthalmology and Biomedical Engineering Director,
More informationCLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA
CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA USHA CHAKRAVARTHY, MD,* YIT YANG, MD, ANDREW LOTERY, MD, FARUQUE GHANCHI, MD, CLARE BAILEY, MD, FRANK G. HOLZ, MD, PHD,** LOUISE
More informationORIGINAL RESEARCH ARTICLE
EJO ISSN 1120-6721 Eur J Ophthalmol 2017; 27 (3): 357-362 DOI: 10.5301/ejo.5000929 ORIGINAL RESEARCH ARTICLE Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal
More informationFLUOCINOLONE ACETONIDE: STEROID LONG ACTING
FLUOCINOLONE ACETONIDE: STEROID LONG ACTING Giuseppe Querques, MD PhD Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita Salute San Raffaele, Milan, Italy Financial Disclosure ADVISORY
More informationSupplement to March Ranibizumab for Visual Impairment in DME: An Overview of The Evidence SPONSORED BY NOVARTIS PHARMA AG
Supplement to March 2018 Ranibizumab for Visual Impairment in DME: An Overview of The Evidence SPONSORED BY NOVARTIS PHARMA AG Ranibizumab for Visual Impairment in DME: An Overview of The Evidence BY PROF.
More informationLong-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
Ophthalmol Ther (2015) 4:51 58 DOI 10.1007/s40123-015-0028-0 CASE REPORT Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant Thomas Bertelmann
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationCombination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.
REVIEW ARTICLE Combination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.net Protocol U Cindy Ung 1, Kareem Moussa 1, Yoshihiro Yonekawa
More informationCharles C. Wykoff MD PhD Rahul N. Khurana MD
HDWallpapers Suprachoroidal Triamcinolone Acetonide with & without Intravitreal Aflibercept for DME: Results of the 6 Month Prospective Phase 1/2 Hulk trial Blanton Eye Institute Charles C. Wykoff MD PhD
More informationRetina Diabetic Macular Edema
Retina Diabetic Macular Edema ILUVIEN A New Approach to the Treatment of Diabetic Macula Edema Pravin U Dugel, MD 1 and Richard Parrish, MD 2 1. Retinal Consultants of Arizona, Phoenix, Arizona, US; Clinical
More informationCURRENT TRENDS IN DIABETIC MACULAR EDEMA TREATMENT. Muge R. Kesen, MD
CURRENT TRENDS IN DIABETIC MACULAR EDEMA TREATMENT Muge R. Kesen, MD No relevant financial interest or relationships DISCLOSURE OBJECTIVES Current trends (evidence based) Review of clinical trials Diabetic
More informationAn updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema
Review Article An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema Jia-Kang Wang 1,2,3,4, Tzu-Lun Huang 1,5, Pei-Yuan Su 1,4,6,
More informationDiabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
More informationOriginal Paper. Ophthalmic Res DOI: /
Original Paper Received: December 19, 216 Accepted: December 19, 216 Published online: February 9, 217 A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN
More informationTREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY
TREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY *Michael W. Stewart Professor and Chairman, Mayo School of Medicine, Department of Ophthalmology,
More informationMANY STUDIES SUPPORT THE VIEW THAT THE NATURAL HIStory
DIABETIC MACULAR EDEMA Personalizing Treatment By Annie Stuart, Contributing Writer Anti-VEGF therapy has been a godsend for many patients with diabetic macular edema. But it s not the whole answer for
More informationDiabetic Macular Oedema To treat or not to treat?
Diabetic Macular Oedema To treat or not to treat? Ms Ranjit Sandhu MBBS MRCOphth MD FRCOphth Consultant Ophthalmic Surgeon Cataract Surgery, Medical Retina & Uveitis The Luton and Dunstable University
More informationDiabetic Macular Edema Treatment in the 21st Century
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationINTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA Pharmacokinetic Considerations
Review INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA Pharmacokinetic Considerations YIT YANG, MBCHB, FRCOPHTH,* CLARE BAILEY, MD, FRCP, FRCOPHTH, ANAT LOEWENSTEIN, MD, MHA, PASCALE MASSIN, MD,
More informationOutcomes of Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Outcomes of Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice John D. Pitcher, MD 1,2 ; Andrew A. Moshfeghi, MD 3 ; Genevieve Lucas, B. Comm. 4 ; Nick Boucher, BS 4
More informationABSTRACT INTRODUCTION
DOI 10.1007/s40123-017-0114-6 ORIGINAL RESEARCH Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective
More informationNew Paradigms in the Management and Treatment of Diabetic Macular Edema
Supplement to March 2016 CME ACTIVITY New Paradigms in the Management and Treatment of Diabetic Macular Edema Pravin U. Dugel, MD Alexander Eaton, MD Nancy M. Holekamp, MD Szilárd Kiss, MD Baruch D. Kuppermann,
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationClinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.
1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417
More informationFusi-Rubiano et al. BMC Ophthalmology (2018) 18:62 https://doi.org/ /s
Fusi-Rubiano et al. BMC Ophthalmology (2018) 18:62 https://doi.org/10.1186/s12886-018-0726-1 RESEARCH ARTICLE Open Access Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the
More informationANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA
January/February 2015 Supplement to ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA A roundtable discussion with Franck Fajnkuchen, MD, and Paolo Lanzetta, MD Case report by Paolo Lanzetta, MD The answers
More informationAbbreviated Drug Evaluation: Fluocinolone acetonide intravitreal implant (Retisert )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAnti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema
Ophthalmic Technology Assessment Anti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema A Report by the American Academy of Ophthalmology Allen C. Ho, MD, Ingrid U. Scott, MD,
More informationFront Line Diabetic Retinopathy What Not to Miss and Why
Front Line Diabetic Retinopathy What Not to Miss and Why David M Brown MD FACS Clinical Professor of Ophthalmology Blanton Eye Institute, Houston Methodist Hospital Baylor College of Medicine Retina Consultants
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 20 Next Review: September 2017 Related Policies 9.03.21 Aqueous Shunts for Glaucoma Intravitreal Corticosteroid Implants Summary An intravitreal implant
More informationCase Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema V Swetha E Jeganathan 1,2 * and Karen Madill 3 1 Department of Ophthalmology,
More informationNew Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationEU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO
EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO Yehia Hashad, M.D. Vice President and Global Therapeutic Area Head
More informationThe treatment of diabetic macular edema (DME) has become one of the most challenging management issues faced by ophthalmologists in
Review Retina The Value of Area Under the Curve Analysis as an Outcome Measure in the Assessment of a Continuous Microdosing Fluocinolone Acetonide Implant (ILUVIEN ) Sepehr Bahadorani 1 and Michael A
More informationPersistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
9:30 AM Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment Lee Jampol, MD OBJECTIVE To assess subsequent visual and anatomic outcomes of eyes with
More informationIntroduction. Carmen A. Puliafito, MD Editor-in-Chief OSLI Retina
Introduction A panel of experts gathered during the 2015 annual meeting of the American Academy of Ophthalmology for a roundtable discussion on how ophthalmologists select patients who may benefit from
More informationTreatment practice in the
Strategies for managing neovascular AMD and in routine clinical care BY ROD MCNEIL Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema
More informationDiabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel
Miss Vasuki Sivagnanavel Consultant Ophthalmologist An update on Diabetic maculopathy Despite advances in the management of diabetes, diabetic retinopathy is already the commonest cause of blindness among
More informationDiabetic macular edema (DME) is a treatable sequela of diabetic retinopathy and a significant cause of visual morbidity among working
Update on the Management of Diabetic Macular Edema Shawn M Iverson 1 and W Lloyd Clark 1,2 1. Palmetto Health - University of South Carolina Medical Group, Columbia, South Carolina, US; 2. Assistant Clinical
More informationCurrent Insight Into Retinal Disease Management: Focus on DME and Intravitreal Corticosteroids
VIEW CASE VIDEOS ONLINE Supplement to March 2015 CME ACTIVITY Current Insight Into Retinal Disease Management: Focus on DME and Intravitreal Corticosteroids Allen C. Ho, MD, Moderator Michael D. Ober,
More informationIntravitreal Corticosteroids in the Management of Diabetic Macular Edema
Curr Ophthalmol Rep (2013) 1:144 149 DOI 10.1007/s40135-013-0015-3 DIABETIC RETINOPATHY: MEDICAL AND SURGICAL THERAPIES (PK KAISER, SECTION EDITOR) Intravitreal Corticosteroids in the Management of Diabetic
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost
More informationApplying New Data to Improve the Standard of Care in Retinal Diseases Managing Macular Edema Associated With Retinal Venous Occlusions
Supplement to November/December 2013 CME Activity Applying New Data to Improve the Standard of Care in Retinal Diseases Managing Macular Edema Associated With Retinal Venous Occlusions By Michael Singer,
More informationParadigm Shift in the treatment of Diabetic Retinopathy. Haytham I. S. Salti, MD Associate Professor
Paradigm Shift in the treatment of Diabetic Retinopathy Haytham I. S. Salti, MD Associate Professor Disclosure No financial interests related to the subject matter of this talk This presentation includes
More informationIntravitreous injections of anti-vascular endothelial growth
Physiology and Pharmacology Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Adam
More informationMacular edema (ME) is the most common
MANAGEMENT OF RETINAL VEIN OCCLUSIONS * Peter A. Campochiaro, MD ABSTRACT Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). The primary cause
More informationOverview of the Pathogenesis of Diabetic Retinopathy
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationProtocol T and More for DR/DME IMPLICATIONS FOR PRACTICE
CME Monograph Protocol T and More for DR/DME IMPLICATIONS FOR PRACTICE Visit https://tinyurl.com/protocoltcme for online testing and instant CME certificate. FACULTY Dante J. Pieramici, MD (Program Chair
More informationWhen and How to Incorporate Steroids for Persistent Diabetic Macular Edema: A Discussion of Real-World Treatment Optimization Strategies
When and How to Incorporate Steroids for Persistent Diabetic Macular Edema: A Discussion of RealWorld Treatment Optimization Strategies ABSTRACT: In the United States, diabetic macular edema (DME) is the
More informationEFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA
Basrah Journal Of Surgery EFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA Salah Zuhair Abed Al-Asadi MB,ChB, FICMS, Lecturer, Department of Surgery, College
More information1/25/2018. Case Management Strategies in Diabetic Retinopathy. Case Study #1: Severe DME. DDOS: 3/31/2016 Va 20/400. Disclosures
Case Management Strategies in Diabetic Retinopathy Disclosures No financial conflict of interest Will discuss off label use of intraocular Bevacizumab (Avastin) for Diabetic Retinopathy Sundeep Dev, MD
More informationHHS Public Access Author manuscript J Vitreoretin Dis. Author manuscript; available in PMC 2017 November 03.
Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection Ankoor R. Shah, M.D. 1,2, Yoshihiro Yonekawa, M.D. 3,7, Bozho Todorich, M.D. Ph.D. 3,7, Lily Van Laere, M.D. 3, Rehan Hussain,
More informationNew STAIRWAY study data shows potential for extended durability with Roche s faricimab in neovascular age-related macular degeneration (namd)
Media Release New STAIRWAY study data shows potential for extended durability with Roche s faricimab in neovascular age-related macular degeneration (namd) Faricimab the first bispecific antibody designed
More informationDrugs vs. DME. Protocol T, the latest in a string of landmark studies by the Diabetic Retinopathy
3 Anti-VEGF Drugs vs. DME The latest study from DRCR.net delivers important clinical information, but questions remain. BY MIRIAM KARMEL, CONTRIBUTING WRITER alfred t. kamajian Protocol T, the latest in
More informationEvolving Issues in Diabetic Vascular Complications: Understanding Ocular Manifestations
Supplement to January/February 2016 CME ACTIVITY Evolving Issues in Diabetic Vascular Complications: Understanding Ocular Manifestations John E. Anderson, MD Jay S. Duker, MD Allen C. Ho, MD John W. Kitchens,
More informationSustained-Release Corticosteroid Options
Sustained-Release Corticosteroid Options Mariana Cabrera, University of Miami Miller School of Medicine Steven Yeh, Emory University Thomas A Albini, University of Miami Miller School of Medicine Journal
More informationOphthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Ophthalmic VEGF Inhibitors Page: 1 of 5 Last Review Date: September 20, 2018 Ophthalmic VEGF Inhibitors
More informationOutcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice
Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice Andrew A. Moshfeghi, MD, MBA 1 ; John D. Pitcher, MD 2,3 ; Genevieve Lucas, B. Comm. 4 ; Nick
More informationDexamethasone implant in diabetic macular edema in real-life situations
(2016) 30, 426 430 2016 Macmillan Publishers Limited All rights reserved 0950-222X/16 www.nature.com/eye CLINICAL STUDY 1 Smt. Kanuri Santhamma Retina Vitreous Centre, L.V. Prasad Institute, Hyderabad,
More informationIntravitreal Corticosteroid Implants
Intravitreal Corticosteroid Implants Policy Number: 9.03.23 Last Review: 4/2018 Origination: 07/2015 Next Review: 4/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationFrom Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014
From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 1. This course is designed to review the important ophthalmic literature that was released between October 2013
More informationIntravitreal Corticosteroid Implants. Description
Subject: Intravitreal Corticosteroid Implants Page: 1 of 20 Last Review Status/Date: June 2015 Intravitreal Corticosteroid Implants Description An intravitreal implant is a drug delivery system, injected
More informationTreatment pathways for Intravitreal therapies in Diabetic Macular Oedema (DMO) Louise Downey Consultant Ophthalmologist MBChB BSc PhD FRCOphth
Treatment pathways for Intravitreal therapies in Diabetic Macular Oedema (DMO) Louise Downey Consultant Ophthalmologist MBChB BSc PhD FRCOphth Disclosures and acknowledgements Financial disclosures; Alcon,
More informationRetinal Neuroprotection and Other Strategies to Treat Atrophic Age-Related Macular Degeneration
Retinal Neuroprotection and Other Strategies to Treat Atrophic Age-Related Macular Degeneration Baruch D Kuppermann, MD, PhD Professor of Ophthalmology and Biomedical Engineering Director, Gavin Herbert
More informationpsivida Transforms into Commercial Stage Specialty BioPharmaceutical Company AAO October 25, 2018 NASDAQ: EYPT
psivida Transforms into Commercial Stage Specialty BioPharmaceutical Company OIS @ AAO October 25, 2018 NASDAQ: EYPT Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
More informationCorporate Presentation August 2018
Corporate Presentation August 218 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationJay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington
Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationCoding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Eylea) Reference Number: CP.PHAR.184 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationIntravitreal fluocinolone acetonide implant (ILUVIEN V R. ) for diabetic macular oedema: a literature review
Special Issue: Macular Diseases: Advances in Diagnostics and Therapeutics Intravitreal fluocinolone acetonide implant (ILUVIEN V R ) for diabetic macular oedema: a literature review Journal of International
More informationA ROUNDTABLE DISCUSSION FEATURING:
Jointly sponsored by the Dulaney Foundation and Retina Today. Supplement to October 2009 New and Emerging Treatment Paradigms for Macular Edema in Retinal Vein Occlusion and Diabetic Retinopathy A ROUNDTABLE
More informationReview Article Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review
Hindawi Ophthalmology Volume 2017, Article ID 2407037, 7 pages https://doi.org/10.1155/2017/2407037 Review Article Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Investor Update Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First Major Treatment Advance in More Than 25 Years for Sight-Threatening Condition
More informationDiabetic Macular Edema
CME SUPPLEMENT TO of NEW FRONTIERS IN THE TREATMENT Diabetic Macular Edema Original Release Date: May 21 Expiration Date: May 3, 216 Two ways to request CME Credit: Visit http://tinyurl.com/frontiersdme
More informationA NOVEL COMPOUND FOR TREATMENT OF WET AMD
A NOVEL COMPOUND FOR TREATMENT OF WET AMD Clinical studies are evaluating a new anti-vegf agent s potential to join current treatment options. BY SARADHA CHEXAL, MD; IVANA GUNDERSON, BS; BRIAN B. BERGER,
More informationComparison of BRVO and CRVO management
Comparison of BRVO and CRVO management Francesco Bandello, MD, FEBO Department of Ophthalmology University Vita-Salute Scientific Institute San Raffaele Milan, Italy 1 Financial Disclosure Advisory Board
More informationMacular edema (ME) results from a complex
DIFFERENTIATING STEROID DELIVERY SYSTEMS FOR MACULAR EDEMA * Baruch D. Kuppermann, MD, PhD ABSTRACT Steroids can intervene with many of the processes that lead to macular edema (ME). Steroids are potent
More informationaflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer
aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationDiabetic Retinopatathy
Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced
More informationFacts About Diabetic Eye Disease
Facts About Diabetic Eye Disease Points to Remember 1. Diabetic eye disease comprises a group of eye conditions that affect people with diabetes. These conditions include diabetic retinopathy, diabetic
More informationMedical Coverage Policy Intravitreal Corticosteroid Implants)
Medical Coverage Policy Intravitreal Corticosteroid Implants) EFFECTIVE DATE:10 01 2015 POLICY LAST UPDATED: 02 07 2017 OVERVIEW An intravitreal implant is a drug delivery system, injected or surgically
More informationClinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
Ophthalmology Volume 12, Article ID 69641, 8 pages doi:1.1155/12/69641 Clinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular
More informationCataract and Diabetic macular edema: What should I do?
Cataract and Diabetic macular edema: What should I do? Irini Chatziralli Ophthalmic Surgeon, University Scholar 2 nd Department of Ophthalmology, University of Athens (Director: Prof P. Theodossiadis)
More informationMolecular Biology of Diabetic Retinopathy
Opportunities for Therapeutic Intervention: Molecular Biology of Diabetic Retinopathy Jointly sponsored by The Dulaney Foundation and DIABETIC MICROVASCULAR COMPLICATIONS TODAY. Release Date: January 2006.
More informationSuprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study
Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study Peter A. Campochiaro, MD, 1 Charles C. Wykoff, MD, 2 David M. Brown, MD, 2 David S. Boyer, MD, 3 Mark Barakat,
More informationThe Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR
The Diabetic Retinopathy Clinical Research Network Management of DME in Eyes with PDR 1 What Has Been Learned? Diabetic Retinopathy Treatment Protocol F: Results suggest that clinically meaningful differences
More informationOpthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company
More informationDexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(2):108-114 https://doi.org/10.3341/kjo.2017.31.2.108 Original Article Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal (STA) Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Oedema Alimera Sciences, Inc. Manufacturer/Sponsor
More informationUpdates and Controversies
Updates and Controversies Philippine Journal of OPHTHALMOLOGY Vascular endothelial growth factor (VEGF) and inflammation. VEGF-A circulates normally in the body and is essential in endothelial cell growth.
More informationDiabetic Retinopathy Update 2017
Diabetic Retinopathy Update 2017 Basis for DR management standards for past 40 years Diabetic Retinopathy Study (DRS) 1971-1989 and Early Treatment of Diabetic Retinopathy Study (ETDRS) 1979-1990 Sundeep
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More informationTreatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
Diabetic Retinopathy Clinical Research Network Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity Version 3.0 April 18, 2014 Treatment of CIDME in Eyes with Good
More informationCorporate Medical Policy
Corporate Medical Policy Intravitreal Implant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravitreal_implant 11/2010 6/2017 6/2018 6/2017 Description of Procedure or Service
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RANIBIZUMAB (Lucentis Novartis Pharmaceuticals Canada Inc.) New Indication: Macular Edema Secondary to Retinal Vein Occlusion Recommendation: The Canadian Drug Expert Committee
More information